Yves Lacourcière

TL;DR: The CONVINCE trial did not demonstrate equivalence of a COER verapamil–based antihypertensive regimen compared with a regimen beginning with a diuretic or -blocker, and data indicate that the effectiveness of calcium-channel therapy in reducing cardiovascular disease is similar but not better than diuresis treatment.

TL;DR: An endothelin-receptor antagonist, bosentan, significantly lowered blood pressure in patients with essential hypertension, suggesting thatendothelin may contribute to elevated blood pressure to patients with mild-to-moderate essential hypertension.

TL;DR: Compared with valsartan, dual-acting LCZ696 provides complementary and fully additive reduction of blood pressure, which suggests that the drug holds promise for treatment of hypertension and cardiovascular disease.

TL;DR: Lowering blood pressure improves diastolic function irrespective of the type of antihypertensive agent used, and there was no significant difference in the change in diastsolic relaxation velocity between the groups.

TL;DR: Elevated PP in systolic hypertension was independent of MAP and was attributable primarily to elevated Zc and reduced effective diameter of the proximal aorta, suggesting that aortic function may play an active role in the pathophysiology of syStolic hypertension.